COMPANY PROFILE

Cirius Therapeutics

Explore full profile

Cirius Therapeutics, a clinical-stage pharmaceutical company

Cascade Charter Township, United StatesFounded 2015Biotech & Life Sciences

Valuation $50–100M Last recorded · 2018

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Cirius Therapeutics

Cirius Therapeutics is a clinical-stage pharmaceutical company dedicated to developing innovative therapies for liver and metabolic diseases, with a primary focus on treating Non-Alcoholic Steatohepatitis (NASH). NASH is a severe liver condition linked to metabolic syndrome, which includes disorders such as insulin resistance, Type 2 diabetes, and obesity. The company operates in the biopharmaceutical sector, targeting healthcare providers and patients affected by these conditions.

Cirius Therapeutics employs a business model centered around research and development (R&D) to create novel drug candidates. Revenue generation is primarily through partnerships, licensing agreements, and potential future sales of approved therapies. The company aims to address significant unmet medical needs in the market, providing effective treatment options for complex liver and metabolic diseases.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2015
Headquarters: Cascade Charter Township, United States
Open positions: None listed
Dealroom signal: 51.9/100
Industry: Health
Sub-industry: Pharmaceutical
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
DEBT✓Debt	Oct 2024	$2.3M	—	Undisclosed	↗
SERIES A✓Equity / VC	Aug 2018	$9M	$36M	Novo Holdings · Frazier Healthcare Partners · Adams Street Partners	—

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Cirius Therapeutics website traffic

Latest recorded traffic for Cirius Therapeutics is 2.8K monthly website visits, down 15.2% over the last three months.

Latest monthly visits2.8K 3-month web change-15.2%

Monthly website visitsOct 2017–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
AFAlpha FusionFusion of leading-edge scientists teaming in Nuclear Physics, Organic Chemistry, and Nuclear Medicine	Osaka, Japan	Operational	—	$12M	$31M
TTTeitur TrophicsCyclic peptide therapeutics for neurodegenerative diseases	Aarhus, Denmark	Operational
TTTay TherapeuticsBiotech platform enhancing patient-specific medicines through advanced discovery and development expertise	Dundee, United Kingdom	Operational
EBExeVir BioCamelid-derived antibody therapies for infectious diseases	Ghent, Belgium	Operational
CTCV6 TherapeuticsCombination therapies enhancing cornerstone cancer and inflammatory treatments	Belfast, United Kingdom	Operational
NTNucleome TherapeuticsDecoding the dark matter of the human genome to discover first-in-class precision medicine	Oxford, United Kingdom	Operational
RBRosa BiotechAI-driven biosensing and diagnostics company providing outcome-focused biosensing for early disease diagnosis and for use in industrial biotechnology	Bristol, United Kingdom	Operational
ASAstronauTxSmall-molecule therapeutics targeting astrocytes for neurodegenerative diseases	Reading, United Kingdom	Operational